Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sirexatamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sirexatamab overview

Sirexatamab (DKN-01, LY-2812176) is under development for the treatment of gastric cancer, metastatic gastric or gastroesophageal junction adenocarcinoma, esophageal cancer, colorectal cancer, advanced gynecological cancers and endometrial cancer. The drug candidate is administered intravenously. It is a monoclonal antibody targeting dickkopf homolog 1 (Dkk-1).
The drug candidate was also under development for the treatment of relapsed or refractory multiple myeloma, metastatic castration-resistant prostate cancer, non-small cell lung cancer, esophageal cancer, fallopian tube cancer, adenocarcinoma of the gastroesophageal junction, epithelial ovarian cancer, peritoneal cancer,  carcinosarcoma (uterine cancer), gallbladder cancer, bile duct cancer, extrahepatic bile duct cancer, hepatocellular Carcinoma and metastatic biliary tract cancer.

Leap Therapeutics overview

Leap Therapeutics is a clinical-stage biopharmaceutical company. It develops novel and targeted drugs to treat patients with different types of cancer. The company’s pipeline includes DKN-01, FL-301, FL-302 and FL-501. DKN-1 is a monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, colorectal cancer and gynecological cancer. FL-301 is a monoclonal antibody that targets Claudin18.2 and is being tested in patients with gastric and pancreatic cancer. FL-302 is a tetravalent bispecific antibody that targets both Claudin18.2 and CD137. FL-501 is an antibody designed to neutralize GDF15 and prevent the binding to its receptor. Leap Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Sirexatamab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.